English
norskBlar i forfatter "Moestue, Siver Andreas"
Viser treff 1-10 av 10
-
Anti-angiogenic therapy affects the relationship between tumor vascular structure and function: a correlation study between micro-CT angiography and DCE-MRI
(Journal article; Tidsskriftartikkel; Peer reviewed, 2016-11-25)Purpose: To compare the effects of two anti-angiogenic drugs, bevacizumab and a cytosolic phospholipase A2-α inhibitor (AVX235), on the relationship between vascular structure and dynamic contrast enhanced (DCE)-MRI measurements in a patient-derived breast cancer xenograft model. Methods: Mice bearing MAS98.12 tumors were randomized into three groups: bevacizumab-treated (n=9), AVX235-treated ... -
Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model
(Journal article; Tidsskriftartikkel; Peer reviewed, 2016-03-07)<b>Background</b> <br> Group IVA cytosolic phospholipase A2 (cPLA2α) plays an important role in tumorigenesis and angiogenesis. It is overexpressed in basal-like breast cancer (BLBC), which is aggressive and usually triple-negative, making it unresponsive to current targeted therapies. Here, we evaluated the anti-angiogenic effects of a specific cPLA2α inhibitor, AVX235, in a patient-derived ... -
Biodistribution of Poly(alkyl cyanoacrylate) Nanoparticles in Mice and Effect on Tumor Infiltration of Macrophages into a Patient-Derived Breast Cancer Xenograft
(Journal article; Tidsskriftartikkel; Peer reviewed, 2021-04-28)We have investigated the biodistribution and tumor macrophage infiltration after intravenous injection of the poly(alkyl cyanoacrylate) nanoparticles (NPs): PEBCA (poly(2-ethyl-butyl cyanoacrylate), PBCA (poly(n-butyl cyanoacrylate), and POCA (poly(octyl cyanoacrylate), in mice. These NPs are structurally similar, have similar PEGylation, and have previously been shown to give large variations in ... -
Detection of phenotype-specific therapeutic vulnerabilities in breast cells using a CRISPR loss-of-function screen
(Journal article; Tidsskriftartikkel; Peer reviewed, 2021-03-24)Cellular phenotype plasticity between the epithelial and mesenchymal states has been linked to metastasis and heterogeneous responses to cancer therapy, and remains a challenge for the treatment of triple-negative breast cancer (TNBC). Here, we used isogenic human breast epithelial cell lines, D492 and D492M, representing the epithelial and mesenchymal phenotypes, respectively. We employed a CRISPR-Cas9 ... -
Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer
(Journal article; Tidsskriftartikkel; Peer reviewed, 2019-05-14)<p><i>Introduction - </i>Glutaminase inhibitors target cancer cells by blocking the conversion of glutamine to glutamate, thereby potentially interfering with anaplerosis and synthesis of amino acids and glutathione. The drug CB-839 has shown promising effects in preclinical experiments and is currently undergoing clinical trials in several human malignancies, including triple-negative breast cancer ... -
Interplay of choline metabolites and genes in patient-derived breast cancer xenografts
(Journal article; Tidsskriftartikkel; Peer reviewed, 2014-01-21)Introduction: Dysregulated choline metabolism is a well-known feature of breast cancer, but the underlying mechanisms are not fully understood. In this study, the metabolomic and transcriptomic characteristics of a large panel of human breast cancer xenograft models were mapped, with focus on choline metabolism. <br> Methods: Tumor specimens from 34 patient-derived xenograft models were collected ... -
Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer
(Journal article; Tidsskriftartikkel; Peer reviewed, 2013)Introduction: The phosphatidylinositol 3-kinase (PI3K) pathway is frequently activated in cancer cells through numerous mutations and epigenetic changes. The recent development of inhibitors targeting different components of the PI3K pathway may represent a valuable treatment alternative. However, predicting efficacy of these drugs is challenging, and methods for therapy monitoring are needed. ... -
Metabolic reprogramming supports the invasive phenotype in malignant melanoma
(Journal article; Tidsskriftartikkel, 2015)Invasiveness is a hallmark of aggressive cancer like malignant melanoma, and factors involved in acquisition or maintenance of an invasive phenotype are attractive targets for therapy. We investigated melanoma phenotype modulation induced by the metastasis-promoting microenvironmental protein S100A4, focusing on the relationship between enhanced cellular motility, dedifferentiation and metabolic ... -
O-GlcNAc Transferase Inhibition Differentially Affects Breast Cancer Subtypes
(Journal article; Tidsskriftartikkel; Peer reviewed, 2019-04-05)Post-translational modifcation of intracellular proteins with a single N-acetylglucosamine sugar (O-GlcNAcylation) regulates signaling, proliferation, metabolism and protein stability. In breast cancer, expression of the enzyme that catalyzes O-GlcNAcylation – O-GlcNAc-transferase (OGT), and the extent of protein O-GlcNAcylation, are upregulated in tumor tissue, and correlate with cancer progression. ... -
Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts
(Journal article; Tidsskriftartikkel; Peer reviewed, 2012-10-23)<p>Antiangiogenic therapy with bevacizumab has shown varying results in breast cancer clinical trials. Identifying robust biomarkers for selecting patients who may benefit from such treatment and for monitoring response is important for the future use of bevacizumab.</p> <p>Two established xenograft models representing basal‐like and luminal‐like breast cancer were used to study bevacizumab ...
